 Todos Medical and its 3CL biology-focused joint venture partner NLC Pharma Limited have announced positive interim data for the Tollovir Phase 2 clinical trial for severe and critical hospitalized coronavirus COVID-19 patients. The firms Tollovir drug candidate for COVID-19 uses a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses. 